TABLE 1.

Transitional MRSA strains and their clinical, phenotypic, and genotypic characteristicsa,c

MRSA isolateDate of isolation (mo/day/yr)SourceInfection siteAge of patient (yr)mec complexSCCmec typebAntimicrobial resistance
WI-25010/03/95CASputum77B1IVaEry, Cli
WI-39805/18/98CAGroin46B1IVc
WI-35611/24/97CAFoot53WTIVaCip
WI-21704/07/95CAToe45B1IVc
WI-21102/23/95CALeg12B1IVa
WI-18008/11/94CAKnee16B1IV*Ery, Cli, Tet, SXT
WI-59112/13/99CAHand6B1IVa
WI-33908/06/97NOSBlood87B1IV*
WI-31901/14/97NOSSputum89B1IV*
WI-36902/02/98NOSSputum4B1IVaEry, Cli
WI-50304/26/99NOSSputum78B1IVcEry, Cli
WI-2301/23/92NOSTrachea1WTIV*
WI-17808/05/94NOSTrachea2 moB1IV*Ery, Cli, Tet
WI-49003/17/99NOSTrachea85B1IV*
WI-1612/02/91NOSRectum44B1IV*
WI-701/15/91NOSHip87WTIV*Ery, Cli
WI-44310/26/98NOSCatheter site72B1IV*
WI-54809/22/99NOSNP11B1IVa
WI-58511/22/99LTCNP36B1IVc
WI-38003/10/98LTCBack89B1IV*
  • a CA, community associated; Cip, ciprofloxacin; Cli, clindamycin; Ery, erythromycin; LTC, long-term care; NOS, nosocomial; SXT, trimethoprim-sulfamethoxazole; Tet, tetracycline; WT, wild-type mec complex.

  • b *, Could not be subtyped.

  • c All isolates were negative for the PVL genes.